Clinical Application of Tumor-specific Anti-tumor Immunity Induced by Tumor Cells Expressing Fas (CD95) Ligand

表达Fas(CD95)配体的肿瘤细胞诱导肿瘤特异性抗肿瘤免疫的临床应用

基本信息

  • 批准号:
    13557097
  • 负责人:
  • 金额:
    $ 8.83万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2001
  • 资助国家:
    日本
  • 起止时间:
    2001 至 2003
  • 项目状态:
    已结题

项目摘要

CD95 ligand (FasL)-expressing tumors cause immunopotentiation following vigorous neutrophil infiltration. Thus, the induction of neutrophil Infiltration by FasL appears to play an important role in tumor rejection. 1) The mechanism by which FasL-expressing tumors cause neutrophil infiltration has not been well understood. Here, we Investigated the role of chemokines in FasL-induced antitumor activity. CXC chemokine receptor 2 (CXCR2) knockout (KO) mice are a powerful tool for studying CXC chemokine-mediate neutrophil infiltration. Thus, we examined the mechanism for the neutrophil recruitment Induced by FasLcDNA-transfected MethA (MethA+FasL) fibrosarcoma using CXCR2 KO mice. MethA+FasL cells were completely rejected in wild-type (WT) and KO mice. MethA+FasL cells Injected i.p. induced the recruitment of both neutrophils and macrophages in peritoneal cavity (PC) of WT but only macrophages in PC of KO mice, although CXC and CC chemokines were released In PC in both mice. Macrophages Inc … More ubated with MethA+FasL cells released CXC and CC chemokines. F4/80-positive macrophages decreased after injection of MethA+FasL cells. Macrophages derived from WI and KO but not neutrophils from WT mice induced the recruitment of neutrophils when adoptively i.p. transferred with MethA+FasL cells into FasL/Fas-deficient mice. The different recruitment of inflammatory cells between WT and KO mice was attributed to bone marrow (BM) cells by BM transfer experiment. These results demonstrated that CXC chemokines are essential for neutrophil recruitment and that macrophages but not neutrophils play a critical role in FasL-induced infiltration of Inflammatory cells and that chemokines played important roles In eradication of FasL-expressing tumor cells and induction of antitumor immunity. 2) Mouse mammary tumor, BJMC3879, has highly metastatic potential. FasLcDNA-transfected BJMC3879 (BJMC+FasL) was established for clinical application of breast cancer. Although It induced neutrophil recruitment, It was not rejected In WT mice. The reason might be that BJMC+FasL was little expressed FasL-protein on cell surface. It could be indicated that the capability of FasL-protein expression depends on a kind of tumor cell. 3) On the other hand, we were developing non-viral vectors for clinical application. We are investigating the effects of Quarternary complex (Qplex) (cDNA+cationlc liposome+protamine+transferin) or polyethilenimine on transfecting rate of a few cell lines. Several problems for clinical application become clear. Less
表达CD 95配体(FasL)的肿瘤在剧烈的中性粒细胞浸润后引起免疫增强。因此,FasL诱导中性粒细胞浸润似乎在肿瘤排斥中起重要作用。1)表达FasL的肿瘤引起中性粒细胞浸润的机制尚未得到很好的理解。在这里,我们研究了趋化因子在FasL诱导的抗肿瘤活性中的作用。CXC趋化因子受体2(CXCR 2)敲除(KO)小鼠是研究CXC趋化因子介导的中性粒细胞浸润的有力工具。因此,我们使用CXCR 2 KO小鼠研究了由FasL cDNA转染的MethA(MethA+FasL)纤维肉瘤诱导的中性粒细胞募集的机制。MethA+FasL细胞在野生型(WT)和KO小鼠中被完全排斥。腹膜内注射MethA+FasL细胞诱导WT小鼠腹腔(PC)中中性粒细胞和巨噬细胞的募集,但KO小鼠PC中仅巨噬细胞的募集,尽管在两种小鼠的PC中均释放CXC和CC趋化因子。Macrophage Inc ...更多信息 用MethA+FasL处理的细胞释放CXC和CC趋化因子。注射MethA+FasL细胞后,F4/80阳性巨噬细胞减少。当用MethA+FasL细胞过继腹膜内转移到FasL/Fas缺陷小鼠中时,来自WI和KO的巨噬细胞而不是来自WT小鼠的中性粒细胞诱导中性粒细胞的募集。通过骨髓转移实验,WT和KO小鼠之间炎性细胞的不同募集归因于骨髓(BM)细胞。这些结果表明,CXC趋化因子是必需的中性粒细胞募集和巨噬细胞,而不是中性粒细胞在FasL诱导的炎性细胞的浸润中发挥关键作用,趋化因子在根除表达FasL的肿瘤细胞和诱导抗肿瘤免疫中发挥重要作用。2)小鼠乳腺肿瘤BJMC 3879具有高度转移潜能。建立了转染FasL cDNA的BJMC 3879(BJMC+FasL)细胞系,为乳腺癌的临床应用奠定了基础。虽然它诱导中性粒细胞募集,但在WT小鼠中没有排斥。其原因可能是BJMC+FasL细胞表面很少表达FasL蛋白。说明FasL蛋白的表达能力取决于肿瘤细胞的种类。3)另一方面,我们正在开发用于临床应用的非病毒载体。我们研究了四元复合物(cDNA+阳离子脂质体+鱼精蛋白+转铁蛋白)或聚乙烯亚胺对几种细胞系转染率的影响。临床应用的几个问题变得清晰。少

项目成果

期刊论文数量(56)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
清水本武: "アポトーシスのすべてアポトーシス制御による治療法:悪性腫瘍"臨床免疫. 38巻特別増刊号. 404-408 (2002)
Mototake Shimizu:“关于细胞凋亡。通过控制细胞凋亡进行治疗:恶性肿瘤”《临床免疫学》第 38 卷特刊(2002 年)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Takeda, Y.: "Does the timing of surgery for breast cancer in relation to the menstrual cycle or geomagnetic activity affect prognoses of premenopausal patients ?."Biomed.Pharmacother.. 57(Supp). 96-103 (2003)
Takeda, Y.:“与月经周期或地磁活动相关的乳腺癌手术时机是否会影响绝经前患者的预后?”Biomed.Pharmacother.. 57(增刊)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Shimizu M, Yoshimoto T, Matsuzawa A, Takeda T.: "Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for Immunotherapy of cancer."Mol.Biotechnol.. 25. 79-87 (2003)
Shimizu M、Yoshimoto T、Matsuzawa A、Takeda T.:“通过电穿孔用 Fas (CD95) 抗原基因和 Fas 配体 (CD95L) 基因转染对肿瘤细胞进行修饰,用于癌症的免疫治疗。”Mol.Biotechnol.. 25. 79-
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y.: "Chronothetrapy for cancer."Biomed. Pharmacother.. 57 (Supp). 92-95 (2003)
Eriguchi M、Levi F、Hisa T、Yanagie H、Nonaka Y、Takeda Y.:“癌症的计时疗法”。Biomed。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Toyota, H.: "Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death than wild-type Bax"Cancer Lett.. 189. 221-230 (2003)
Toyota, H.:“钙蛋白酶诱导的 Bax 裂解产物是比野生型 Bax 更有效的细胞凋亡诱导剂”Cancer Lett.. 189. 221-230 (2003)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAKEDA Yasutaka其他文献

TAKEDA Yasutaka的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TAKEDA Yasutaka', 18)}}的其他基金

Basic study for Analysis of Intractable Resistant Tumor Cells and their Overcoming in Cancer Gene Therapy
难治性耐药肿瘤细胞分析及其在癌症基因治疗中克服的基础研究
  • 批准号:
    14571125
  • 财政年份:
    2002
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic study for. Cancer Gene Therapy by Antitumor Effects Using Fas-Fas Ligand-Mediated Apoptosis
基础学习。
  • 批准号:
    12671144
  • 财政年份:
    2000
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A study for cancer gene therapy through Fas-mediated apoptosis
通过 Fas 介导的细胞凋亡进行癌症基因治疗的研究
  • 批准号:
    10671099
  • 财政年份:
    1998
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A study on tumor cell/cell interactions using mouse mammary tumor models
使用小鼠乳腺肿瘤模型研究肿瘤细胞/细胞相互作用
  • 批准号:
    08671337
  • 财政年份:
    1996
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study of Tumor Progression in vivo and in vitro using
使用体内和体外肿瘤进展研究
  • 批准号:
    06671186
  • 财政年份:
    1994
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Development of Organ- and Cell-specific In Vivo Genome Editing Technique as a Novel Approach for Cancer Gene Therapy
开发器官和细胞特异性体内基因组编辑技术作为癌症基因治疗的新方法
  • 批准号:
    23H02763
  • 财政年份:
    2023
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of a novel cancer gene therapy targeting prostate cancer stem cell
开发针对前列腺癌干细胞的新型癌症基因疗法
  • 批准号:
    22K07252
  • 财政年份:
    2022
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering non-proliferating-but-active (NPBA) probiotic for breast-cancer gene therapy
用于乳腺癌基因治疗的工程非增殖但有活性(NPBA)益生菌
  • 批准号:
    10350147
  • 财政年份:
    2021
  • 资助金额:
    $ 8.83万
  • 项目类别:
Engineering non-proliferating-but-active (NPBA) probiotic for breast-cancer gene therapy
用于乳腺癌基因治疗的工程非增殖但有活性(NPBA)益生菌
  • 批准号:
    10533816
  • 财政年份:
    2021
  • 资助金额:
    $ 8.83万
  • 项目类别:
Development of invasive bladder cancer gene therapy focusing on genomic instability
专注于基因组不稳定性的侵袭性膀胱癌基因治疗的发展
  • 批准号:
    20K18096
  • 财政年份:
    2020
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Japan Original Cancer Gene Therapy by Inhibition of Multiple Molecules Using Decoy Strategy
日本原创癌症基因疗法,利用诱饵策略抑制多分子
  • 批准号:
    16H05513
  • 财政年份:
    2016
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of a novel RNA trans-splicing molecule for cancer gene therapy targeting to cancer-type organic anion transporting polypeptide 1B3
开发一种新型RNA转拼分子,用于针对癌症型有机阴离子转运多肽1B3的癌症基因治疗
  • 批准号:
    15K14994
  • 财政年份:
    2015
  • 资助金额:
    $ 8.83万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Ovarian cancer gene therapy using HPV pseudovirion
使用 HPV 假病毒颗粒进行卵巢癌基因治疗
  • 批准号:
    9026581
  • 财政年份:
    2014
  • 资助金额:
    $ 8.83万
  • 项目类别:
Ovarian cancer gene therapy using HPV pseudovirion
使用 HPV 假病毒颗粒进行卵巢癌基因治疗
  • 批准号:
    8840196
  • 财政年份:
    2014
  • 资助金额:
    $ 8.83万
  • 项目类别:
Ovarian cancer gene therapy using HPV pseudovirion
使用 HPV 假病毒颗粒进行卵巢癌基因治疗
  • 批准号:
    8636544
  • 财政年份:
    2014
  • 资助金额:
    $ 8.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了